Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.54 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | CTRC | Q99895 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931017 | 0.85 | ADORA2A (0.66) | ADORA2AADORA1KMOSMN1; SMN2MCL1 | |
| SCHEMBL2259547 | 0.83 | ADORA3 (0.56) | ADORA1KMOCTRCSMN1; SMN2MCL1 | |
| SCHEMBL930558 | 0.83 | KMO (0.61) | ADORA2AADORA1KMODHODH | |
| SCHEMBL3450486 | 0.76 | MEN1 (0.47) | ADORA2AADORA1SMN1; SMN2ADORA3MEN1 | |
| SCHEMBL17595055 | 0.75 | MCL1 (0.54) | SMN1; SMN2MCL1ADORA3ALDH1A1ALPL | |
| SCHEMBL930471 | 0.75 | ADORA2A (0.59) | ADORA2AADORA1SMN1; SMN2ADORA3MEN1 | |
| SCHEMBL476659 | 0.74 | CTRC (0.62) | ADORA1CTRCSMN1; SMN2MCL1ADORA3 | |
| SCHEMBL28340647 | 0.74 | TSHR (0.54) | MCL1MEN1KMT2AALDH1A1 | |
| SCHEMBL929260 | 0.74 | ADORA2A (0.60) | ADORA2AADORA1ADORA3 | |
| SCHEMBL929982 | 0.74 | ADORA2A (0.60) | ADORA2AADORA1MCL1ADORA3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1720553-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R&D) LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005079801-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R & D) LTD (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885KMO 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.